Decision Nº M/04/009 from Competition and Consumer Protection Commission, 2004-03-04

CourtCompetition and Consumer Protection Commission (Ire)
PartiesCSL Animal Health,Pfizer Inc
Date04 March 2004
Decision NumberM/04/009
StatusPreliminary investigation (Phase 1)
Decision Date04 March 2004
Determination of the Competition Authority
Determination No. M/04/009 of the Competition Authority, dated 4th March
2004, under Section 21 of the Competition Act 2002
Notification No. M/04/009 – The acquisition by Pfizer Inc. of CSL Animal
Health, a division of CSL Limited
Introduction
1. On 9th February 2004 the Competition Authority, in accordance with Section
18(1) of the Competition Act 2002 (“the Act”), was notified, on a mandatory
basis, of a proposal whereby Pfizer Inc. (“Pfizer”) would acquire CSL Animal
Health, a division of CSL Limited (“CSL”) (“the proposed acquisition”).
The sale agreements were signed on 16th December 2003. The proposed
acquisition is global in nature and would occur by way of purchase of assets in
Australia and New Zealand and shares in the United States.
The Parties
2. Pfizer is a publicly owned, global pharmaceutical company and parent of the
Pfizer group of companies, which develop, manufacture and market prescription
medicines for humans and animals, and consumer healthcare products.
3. CSL Animal Health is owned by CSL, a publicly owned, Australian
pharmaceutical company, with subsidiaries in Australia, New Zealand, Europe
and the United States. CSL operates four business units: CSL Human Health -
manufactures and supplies vaccines for human use, and markets antibiotics and
pharmaceutical products supplied by other manufacturers; JHR Biosciences -
manufactures and supplies cell culture reagents; ZLB Plasma Services - supplies
plasma to a division of CSL Human Health, and manufactures and supplies
plasma-derived products; and CSL Animal Health - develops, manufactures and
markets vaccines for the prevention of disease in livestock and companion
animals, as well as diagnostics for livestock. It has manufacturing facilities in
Australia, New Zealand and the United States.
Commercial Rationale
4. Pfizer outlined the strategic objectives of the proposed acquisition, as follows:
It will provide Pfizer with a complementary range of products and
significantly increase its sales of vaccines in Australia;
It will secure Pfizer’s continued control of Spirovac, a cattle reproductive
vaccine project that is licensed to Pfizer by CSL Animal Health; and
Pfizer will acquire CSL Animal Health’s product development projects.
1

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT